ClinicalTrials.Veeva

Menu

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

E

EV Clinical Trials

Status and phase

Completed
Phase 4

Conditions

Contact Lens Discomfort
Contact Lens
Contact Lens Dryness

Treatments

Drug: Lifitegrast

Study type

Interventional

Funder types

Other

Identifiers

NCT03686878
LF5-CLD

Details and patient eligibility

About

The most common reason for contact lens discontinuation is contact lens discomfort. The investigators believe that inflammation plays a role in contact lens discomfort and the use of lifitegrast 5% ophthalmic solution may reduce end of the day contact lens discomfort. This study will enroll 21 contact lens users who will be receiving lifitegrast 5% ophthalmic solution and monitor the contact lens discomfort for a 8 week period while.

Full description

Contact lens discontinuation is mostly associated with ocular discomfort. Most patients identifying dryness as the primary reason for contact lens discontinuation. Patients often resort to contact lens solutions, lubricating and/or rewetting drops to temporality improve their contact lens wearing experience. Clinicians often resort to changing contact lens designs, solutions and wearing modalities to improve comfort.

Contact lens discomfort is believed to be mediated by many factors including inflammation and very similar in clinical symptoms of dry eye disease and symptoms of dryness.

Lifitegrast 5.0% ophthalmic solution is an FDA approved solution for the management of signs and symptoms of dryness of dry eye disease. Studies have shown lifitegrast 5% ophthalmic solution may work by blocking the interaction between ICAM-1 and LFA-1 leading to a decrease in activation and recruitment of T-cells, an initial step in inflammation.

The safety and efficacy of Xiidra has been studied in four, 12 week clinical trials involving over 2,100 patients for signs (https://www.xiidra-ecp.com/efficacy-treating-signs) and symptoms (https://www.xiidra-ecp.com/efficacy-symptom-improvement).

The purpose of this open label, interventional study is to examine the effect of lifitegrast 5% ophthalmic solution in contact lens wearing experience by using the CLDEQ-8.

Enrollment

21 patients

Sex

All

Ages

21+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Agree with study protocol
  2. Provide Informed Consent
  3. Age 21 or over
  4. Previous 10 months history of self-assessed comfortable wear samfilcon A contact lenses

Exclusion criteria

  1. Unable or unwilling to comply with study protocol

  2. Unable of unwilling to provide Informed consent

  3. Self-reported symptomatic intolerance of contact lenses

  4. History of an active anterior segment, eyelids, eyelashes, corneal or conjunctival pathology, ongoing ocular infection, inflammation or any other ocular problem that would require management with additional topical ophthalmic medications.

  5. Have had a history of corneal surgery (corneal transplants, LASIK, PRK).

Trial design

Primary purpose

Supportive Care

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

21 participants in 1 patient group

Intervention Group
Experimental group
Description:
Lifitegrast 5% ophthalmic solution group
Treatment:
Drug: Lifitegrast

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems